Introduction {#s1}
============

The rising incidence of *Neisseria gonorrhoeae* infection and antimicrobial resistance imperils effective therapy for gonococcal infections ([@bib6]; [@bib12]; [@bib16]; [@bib25]). Current first-line therapy for gonorrhea relies on the extended spectrum cephalosporin ceftriaxone (CRO) as the backbone of treatment. Dual therapy with azithromycin was intended to delay the emergence of resistance, but rising azithromycin resistance rates have been reported ([@bib25]; [@bib43]), resulting in revision of United Kingdom treatment guidelines to CRO monotherapy ([@bib18]). With no clear next-line agent, gonococcal resistance to ESCs is a problem of paramount clinical importance, illustrated by recent reports of treatment failure and global spread of a multidrug-resistant strain ([@bib16]; [@bib17]).

Rapid point-of-care diagnostics for antimicrobial susceptibility could help ensure efficacious treatment and improve stewardship ([@bib8]; [@bib51]), and genotypic testing for known resistance determinants has been implemented ([@bib2]; [@bib18]). In *N. gonorrhoeae*, reduced susceptibility to ceftriaxone (CRO^RS^) is most commonly associated with genetic variation in *penA* ([@bib33]; [@bib58]; [@bib61]). *penA* encodes PBP2, which is predicted to be the primary target of ESCs by homology to *E. coli* ([@bib26]); in agreement with this model, *penA* mutation and altered PBP2 affinity is the major mechanism of reduced ESC susceptibility in gonococci ([@bib14]; [@bib40]; [@bib50]). Because characterized *penA* alleles correlate very strongly with phenotypic CRO^RS^ in collections of clinical gonococcal isolates, the development of *penA*-targeted molecular diagnostic tests to rapidly evaluate gonococcal cephalosporin susceptibility is underway ([@bib13]; [@bib62]).

However, these characterized collections often include isolates with phenotypic ESC^RS^ that is not attributable to *penA* variation ([@bib12]; [@bib19]; [@bib41]). For example, a recent report ([@bib1]) described the clinical gonococcal isolate GCGS1095, which has a cefixime (CFX) minimum inhibitory concentration (MIC) of 1 μg/mL and a CRO MIC of 0.5 µg/mL. These values are above the Center for Disease Control and Prevention's Gonococcal Isolate Surveillance Project (GISP) threshold values for CFX^RS^ (0.25 µg/mL) and CRO^RS^ (0.125 μg/mL) ([@bib25]). The type IX (non-mosaic) *penA* allele found in this isolate, also designated NG-STAR 9.001, is not known to contribute to reduced cephalosporin susceptibility and is found in many ESC susceptible isolates ([@bib57]).

Loci distinct from *penA* can also contribute to ESC^RS^. These include mutations in *porB* that decrease drug permeability, mutations that enhance drug efflux by the MtrCDE pump, and non-mosaic mutations in penicillin-binding proteins ([@bib33]; [@bib58]). Mutations in *pilQ* have arisen during in vitro selection for cephalosporin resistance, although these variants have not been observed in clinical isolates ([@bib22]). Considering these other resistance-associated loci in addition to *penA* has been proposed as a way to refine sequence-based prediction of cephalosporin susceptibility ([@bib15]). However, the genotype of GCGS1095 at these loci does not explain its high-level CRO^RS^ phenotype ([@bib1]). Rapid genotypic diagnostic tests for known resistance mutations would therefore misclassify this strain as CRO susceptible. Defining the basis for ESC^RS^ in this isolate and others like it is critical for the development of robust sequence-based diagnostics of antimicrobial susceptibility, for supporting public health genomic and phenotypic surveillance programs, and for understanding the biology underlying cephalosporin resistance.

Here, we employed an experimental transformation-based approach to identify the genetic basis of reduced susceptibility in three clinical isolates with high-level CRO^RS^. We found that each of these isolates has unique mutations in the RNA polymerase holoenzyme (RNAP) that cause CRO^RS^. One of these RNAP mutations is also present in a clinical isolate from the U.K., belonging to a genetically distinct clade, that has otherwise unexplained CRO^RS^. We also identified an additional two RNAP mutations that arose de novo to cause CRO^RS^ in vitro. Furthermore, introducing RNAP mutations into diverse clinical isolates from multiple lineages was sufficient to cause high-level phenotypic CRO^RS^, underscoring the ability of isolates from circulating clades to develop CRO^RS^ via a single mutation in RNA polymerase.

Results {#s2}
=======

A single missense mutation in *rpoB* is the genetic basis for reduced ceftriaxone susceptibility in the clinical isolate GCGS1095 {#s2-1}
---------------------------------------------------------------------------------------------------------------------------------

To identify the genetic basis of reduced susceptibility in GCGS1095, we transformed a ceftriaxone susceptible (CRO^S^) recipient strain with genomic DNA from GCGS1095. We reasoned that minimizing the genetic distance between the resistant donor and susceptible recipient would improve the likelihood of identifying the causative locus for CRO^RS^ and would reduce potentially confounding effects of divergent genomic backgrounds. Consequently, we selected GCGS0457, a close phylogenetic neighbor of GCGS1095 ([Figure 1](#fig1){ref-type="fig"}), as the CRO^S^ recipient for these experiments. Transformants were selected on CRO plates, and those that acquired the CRO^RS^ phenotype were characterized by whole genome sequencing to determine which variants they had inherited from GCGS1095.

![RNA polymerase-mediated reduced cephalosporin susceptibility among gonococcal isolates.\
Maximum likelihood phylogeny of the 1102 isolates of the GISP dataset and one United Kingdom isolate (GCPH44). Most high-level reduced cephalosporin susceptibility (MIC ≥0.125 μg/mL) in this dataset is associated with the mosaic *penA* XXXIV allele, but some isolates with high MICs lack this allele. In four of these isolates -- GCGS1095, GCGS1014, GCGS1013 (inset, red-marked leaves) and the U.K. isolate GCPH44 (orange arrow) -- CRO^RS^ is caused by mutations in the RNA polymerase holoenzyme. Transformation of the CRO^RS^ allele *rpoB1* from GCGS1095 confers phenotypic reduced susceptibility to the phylogenetic neighbor GCGS0457 (inset, pink-marked leaf) and to other susceptible clinical isolates (black arrowheads). The isolate GCGS0364 (gray arrowhead, denoted with \*) spontaneously develops CRO^RS^ via *rpoB* mutation in vitro.](elife-51407-fig1){#fig1}

We recovered multiple CRO^RS^ transformants. GCGS0457 did not develop spontaneous CRO^RS^ during culture or when transformed with autologous GCGS0457 genomic DNA. Whole genome sequencing of the CRO^RS^ transformants showed that each transformant inherited the same single nucleotide polymorphism (SNP) in *rpoB* (nucleotide change G602A), which encodes the RNA polymerase beta subunit RpoB (amino acid substitution R201H) ([Figure 2](#fig2){ref-type="fig"}). We named this allele *rpoB1*. These CRO^RS^ transformants did not acquire variants in genes known to contribute to reduced cephalosporin susceptibility, such as *penA*, *ponA*, *pilQ*, or *mtr* ([@bib15]).

![Location of CRO^RS^-associated RNA polymerase mutations.\
(**A**) Alignment of mutant RNA polymerase alleles associated with reduced ceftriaxone susceptibility. (**B**) Crystal structure of the RNA polymerase holoenzyme from *E. coli* by Zuo et al. (PDB 4YLO) ([@bib64]), showing the location of the residues homologous to *N. gonorrhoeae* RpoB R201 (magenta), G158 (yellow), and P157 (orange). The flexible region of σ^70^ 1.1 that includes the variant positions of *rpoD1* and *rpoD1* is not included in this structure, but is predicted to interact with this region of RpoB ([@bib36]).](elife-51407-fig2){#fig2}

As RNA polymerase mutations have not been associated with cephalosporin resistance in *Neisseria*, we tested whether the *rpoB1* mutation is sufficient to confer CRO^RS^. We performed directed transformation of GCGS0457 with a \~ 1.5 kilobase PCR product surrounding the variant position of *rpoB1*. With the exception of the single *rpoB* G602A nucleotide change, the sequence of this PCR product was identical to the parental GCGS0457 sequence. Transformation with the *rpoB1* allele amplified from GCGS1095 yielded multiple CRO^RS^ transformants, whereas transformation with control PCR products amplified from a strain containing wild-type *rpoB* yielded none. Sanger sequencing confirmed the presence of the expected SNP in each resistant transformant. Representative CRO^RS^ transformants were further examined by whole genome sequencing, which ruled out spontaneous mutations. The CRO MIC of the *rpoB1* transformant strain GCGS0457 RpoB^R201H^ was 0.19 μg/mL, a more than ten-fold increase from recipient strain GCGS0457 (CRO MIC 0.012 μg/mL) ([Table 1](#table1){ref-type="table"}). This transformant MIC is similar to the MIC of the parental CRO^RS^ isolate GCGS1095 ([Table 1](#table1){ref-type="table"}), indicating that introduction of this SNP is sufficient to fully recapitulate the CRO^RS^ phenotype in the GCGS0457 background.

###### Selected strains, phenotypic ceftriaxone susceptibility, and relevant genotypes.

  strain             CRO MIC (μg/mL)   *penA* (PBP2)                        *ponA* (PBP1)   PorB 120/121   RpoB              RpoD
  ------------------ ----------------- ------------------------------------ --------------- -------------- ----------------- -------------------
  GCGS0457           0.012             Type IX non-mosaic (NG STAR 9.001)   421P            120G/121V      wildtype          wildtype
  GCGS1095           0.19              Type IX non-mosaic (NG STAR 9.001)   421P            120N/121A      R201H (*rpoB1*)   wildtype
  GCGS1014           0.125             Type IX non-mosaic (NG STAR 9.001)   421P            120D/121A      wildtype          E98K (*rpoD1*)
  GCGS1013           0.19              Type IX non-mosaic (NG STAR 9.001)   421P            120G/121A      wildtype          Δ92--95 (*rpoD2*)
  GCPH44             0.125             Type II non-mosaic (NG STAR 2.001)   421L            120G/121A      H553N             Δ92--95 (*rpoD2*)
  GCGS0457 *rpoB1*   0.19              Type IX non-mosaic (NG STAR 9.001)   421P            120G/121V      R201H (*rpoB1)*   wildtype
  GCGS0457 *rpoD1*   0.125             Type IX non-mosaic (NG STAR 9.001)   421P            120G/121V      wildtype          E98K (*rpoD1*)
  GCGS0457 *rpoD2*   0.19              Type IX non-mosaic (NG STAR 9.001)   421P            120G/121V      wildtype          Δ92--95 (*rpoD2*)
  GCGS0364           0.023             Type IX non-mosaic (NG STAR 9.001)   421P            120K/121D      wildtype          wildtype
  GCGS0364 *rpoB2*   0.5               Type IX non-mosaic (NG STAR 9.001)   421P            120K/121D      G158V (*rpoB2*)   wildtype
  GCGS0364 *rpoB3*   0.75              Type IX non-mosaic (NG STAR 9.001)   421P            120K/121D      P157L (*rpoB3*)   wildtype

RNA polymerase mutations explain CRO^RS^ in other clinical isolates {#s2-2}
-------------------------------------------------------------------

GCGS1014 is a phylogenetic neighbor of GCGS1095 that also has unexplained CRO^RS^ ([Figure 1](#fig1){ref-type="fig"}; [Table 1](#table1){ref-type="table"}). The close phylogenetic relationship between these isolates led us to hypothesize that they would share the same mechanism of CRO^RS^. However, the GCGS1014 isolate lacks the *rpoB1* allele identified in GCGS1095. In fact, among the 1102 sequenced isolates in the GISP collection, the *rpoB1* allele is unique to GCGS1095 ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

To define the genetic basis of CRO^RS^ in GCGS1014, we used the same unbiased transformation approach as described above, again using the CRO^S^ neighbor GCGS0457 as the recipient strain. The CRO^RS^ transformants from GCGS1014 gDNA did not have mutations in *rpoB* or in other characterized resistance-associated genes. Instead, all CRO^RS^ transformants inherited a single nucleotide substitution in *rpoD* (nucleotide G292A), which encodes the major housekeeping sigma factor RpoD, or σ^70^ (amino acid substitution E98K) ([Figure 2](#fig2){ref-type="fig"}). This allele, *rpoD1*, is present in the CRO^RS^ donor GCGS1014 but not in GCGS1095 ([Table 1](#table1){ref-type="table"}) or in any other isolate from the GISP collection ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). To test the ability of the *rpoD1* allele to confer CRO^RS^ to a susceptible strain, we transformed GCGS0457 with a \~ 1.5 kilobase PCR product that includes the single variant position in *rpoD1*. As with the directed transformation of *rpoB1*, the *rpoD1* allele amplified from GCGS1014 transformed GCGS0457 to high-level CRO^RS^, but control PCR products amplified from strains with wild-type *rpoD* did not. The presence of the *rpoD1* allele in resistant transformants was confirmed by Sanger sequencing and by whole genome sequencing, which also ruled out the possibility of spontaneous mutations causing the CRO^RS^ phenotype. The *rpoD1* transformant strain GCGS0457 RpoD^E98K^ had a CRO MIC of 0.125 μg/mL, the same as that of the parental CRO^RS^ isolate GCGS1014 ([Table 1](#table1){ref-type="table"}).

As the CRO^RS^ phenotypes in GCGS1095 and GCGS1014 are caused by distinct RNAP mutations, we examined alleles of RNAP components in each of the 1102 genomes in the GISP collection ([@bib19]) to identify additional RNAP variants that might explain other cases of uncharacterized CRO^RS^ ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We found that the isolate GCGS1013 has a 12-basepair in-frame internal deletion in *rpoD*, resulting in the deletion of amino acids 92--95 ([Figure 2](#fig2){ref-type="fig"}); GCGS1013 has a CRO^RS^ phenotype but does not have a CRO^RS^-associated *penA* allele (CRO MIC 0.19 μg/mL; [Table 1](#table1){ref-type="table"}). Transformation of the GCGS1013 *rpoD* allele, *rpoD2*, into the susceptible recipient GCGS0457 increased CRO resistance to 0.19 μg/mL ([Table 1](#table1){ref-type="table"}). The *rpoD2* allele is also present in a clinical gonococcal isolate from a recent United Kingdom strain collection ([@bib11]). This isolate, GCPH44 (genome accession number SRR3360905), has a CRO^RS^ phenotype (CRO MIC 0.125 μg/mL) and belongs to distinct phylogenetic lineage from that of GCGS1013 ([Figure 1](#fig1){ref-type="fig"}). Like GCGS1013, the CRO^RS^ phenotype of GCPH44 is not attributable to variation in *penA* or other known resistance determinants ([Table 1](#table1){ref-type="table"}).

The amino acids deleted in the *rpoD2* allele (Δ92--95) are in a similar region of the RpoD protein as the single amino acid change in the *rpoD1* allele (E98K) ([Figure 2A](#fig2){ref-type="fig"}). This flexible portion of the σ^70^ 1.1 domain is not included in published RNA polymerase holoenzyme crystal structures. Modeling of *E. coli* RNAP predicts that σ^70^ 1.1 interacts with the DNA channel formed by the β subunit encoded by *rpoB* prior to open complex formation ([@bib36]). In *E. coli*, the RpoB residue homologous to the substituted amino acid in *rpoB1* (*E. coli* RpoB R197) is located on the surface of the β lobe structure that makes up this same channel ([Figure 2B](#fig2){ref-type="fig"}). Taken together, these results demonstrate that RNAP-mediated CRO^RS^ has arisen multiple times in clinical isolates of *N. gonorrhoeae*, and that these different mutations affect a similar region of the RNAP holoenzyme. They may therefore act via a similar mechanism to effect phenotypic CRO^RS^.

Clinical isolates from multiple lineages can achieve high-level CRO^RS^ via a single nucleotide change in *rpoB* {#s2-3}
----------------------------------------------------------------------------------------------------------------

The *rpoB1* and *rpoD1* alleles each differ from wild-type by a single nucleotide. The ability of these mutations to cause high-level CRO^RS^ when introduced into the susceptible strain GCGS0457 indicates that some gonococcal isolates are a single-step mutation from CRO^RS^. Because three of the four clinical isolates we identified with RNAP-mediated CRO^RS^ are clustered in one part of the gonococcal phylogeny ([Figure 1](#fig1){ref-type="fig"}), we tested whether acquisition of CRO^RS^ via this pathway is limited to strains within this particular clade -- which would suggest that one or more genetic background factors are required -- or whether RNAP mutation represents a broadly accessible evolutionary trajectory to CRO^RS^.

To address this question, we sought to transform genetically diverse recipient strains to CRO^RS^ with the *rpoB1* allele. In a panel of 17 clinical isolates from the GISP collection, we found five additional recipients dispersed throughout the phylogeny that acquired phenotypic CRO^RS^ following directed transformation with *rpoB1* ([Figure 1](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). The remaining 12 isolates, as well as the laboratory strain 28BL, did not readily produce CRO^RS^ *rpoB1* transformants after 1--2 transformation attempts. These results indicate that genetic background compatibility with this resistance mechanism is not limited to a single gonococcal lineage, to recipients with particular alleles of any RNA polymerase component ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), or to recipients with variants in *ponA* or *mtrR* associated with β-lactam resistance ([@bib15]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). As transformation efficiency in these diverse isolates is variable, the failure to recover CRO^RS^ transformants from any particular strain following a single transformation attempt may reflect low efficiency rather than an absolute genetic incompatibility with an RNAP-mediated resistance mechanism. The successful transformation of *rpoB1* into these five additional isolates therefore represents a lower bound on, rather than exact count of, the number of isolates in this panel that can develop resistance via this pathway.

A clinical isolate develops high-level CRO^RS ^in vitro through spontaneous *rpoB* mutation {#s2-4}
-------------------------------------------------------------------------------------------

While screening isolates for genetic compatibility with *rpoB*-mediated CRO^RS^ in the directed transformation experiments described above, we tested isolates in parallel for spontaneous development of CRO^RS^. We found that the CRO^S^ isolate GCGS0364, located in a similar part of the phylogeny as the resistant isolates GCGS1095, GCGS1014, and GCGS1013 ([Figure 1](#fig1){ref-type="fig"}), produced stably CRO^RS^ derivatives when exposed to CRO in vitro. Sanger sequencing of the *rpoB* locus in two of these derivatives identified two different spontaneous *rpoB* mutations: *rpoB2* (nucleotide change C470T, amino acid change P157L) and *rpoB3* (nucleotide change G473T, amino acid change G158V) ([Figure 2A](#fig2){ref-type="fig"}). These de novo RpoB mutations are predicted to occur in the same β-sheet as the *rpoB1* variant position (R201H) identified in GCGS1095 ([Figure 2B](#fig2){ref-type="fig"}). Directed transformation of *rpoB2* or *rpoB3* into the parental (CRO^S^) GCGS0364 isolate conferred phenotypic CRO^RS^, increasing the CRO MIC more than 20-fold from 0.023 μg/mL to 0.5--0.75 μg/mL ([Table 1](#table1){ref-type="table"}).

RNAP-mediated CRO^RS^ acts via a cephalosporin-specific mechanism {#s2-5}
-----------------------------------------------------------------

Becasue optimal RNA polymerase functionality is required for bacterial fitness, we tested the hypothesis that these RNAP mutations are not specific cephalosporin resistance mutations, but instead cause a slow-growth or general stress response phenotype that nonspecifically increases resistance to diverse classes of antimicrobial compounds.

As expected, the *rpoB1*, *rpoD1*, and *rpoD2* alleles conferred reduced susceptibility to ceftriaxone as well as cefixime (another third-generation cephalosporin) when transformed into the CRO^S^ recipient GCGS0457. However, these alleles did not affect susceptibility to antimicrobial drugs that do not target the cell wall, including ciprofloxacin, tetracycline, azithromycin, and rifampicin. Surprisingly, these mutations also failed to confer resistance to the non-cephalosporin β-lactams penicillin and ertapenem. The apparent cephalosporin specificity of these RNAP mutations in the GCGS0457 background is consistent with the antibiotic susceptibility profiles of the three CRO^RS^ clinical isolates in which they were first identified (GCGS1095 for *rpoB1*, GCGS1014 for *rpoD1*, and GCGS1013 for *rpoD2*) ([Table 2](#table2){ref-type="table"}).

###### Antibiotic susceptibility profiles of CRO^RS^ strains with RNAP mutations.

  Strain                  MIC (μg/ml)                                             
  ----------------------- ------------- ------- ----- ------- ------ --- -------- ---------
  GCGS0457                0.012         0.016   2     0.016   0.25   1   ≤0.015   0.125
  GCGS1095                0.19          1       2     0.032   0.5    1   ≤0.015   ≤0.0625
  GCGS1014                0.125         0.5     1.5   0.032   0.25   1   ≤0.015   ≤0.0625
  GCGS1013                0.19          0.5     1.5   0.023   0.5    1   ≤0.015   ≤0.0625
  GCGS0457 RpoB^R201H^    0.19          \>0.5   2     0.047   0.25   1   ≤0.015   ≤0.0625
  GCGS0457 RpoD^E98K^     0.125         0.5     1.5   0.023   0.25   1   ≤0.015   ≤0.0625
  GCGS0457 RpoD^Δ92-95^   0.19          0.5     2     0.023   0.25   1   ≤0.015   ≤0.0625

GCGS0457 *rpoB1* and GCGS0457 *rpoD1* transformants were further examined for evidence of a slow growth phenotype that might increase antibiotic tolerance. When grown on GCB agar (Difco), neither of these transformants had a reduced growth rate compared to the parental GCGS0457 strain ([Figure 3A](#fig3){ref-type="fig"}). Furthermore, the *rpoB1* and *rpoD1* transformants had no gross defects in cell morphology by transmission electron microscopy (TEM) ([Figure 3B](#fig3){ref-type="fig"}), although transformants were slightly smaller than the parental GCGS0457 strain ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Taken together, these results do not support the hypothesis that RNAP mutations reduce CRO susceptibility via a slow growth or nonspecific tolerance phenotype.

![RNA polymerase mutations do not change growth phenotypes.\
(**A**) Growth of GCGS0457 and RNAP mutant transformants on solid GCB agar (mean and standard deviation of three technical replicates shown, representative of two independent experiments). RNAP mutations do not result in a growth rate defect. (**B**) Transmission electron micrographs of GCGS0457 and RNAP mutant transformants. CRO^RS^ transformants are slightly smaller than the parental GCGS0457 strain, but are otherwise morphologically similar.](elife-51407-fig3){#fig3}

CRO^RS^-associated RNAP mutations induce widespread transcriptional changes {#s2-6}
---------------------------------------------------------------------------

To measure the functional effect of the *rpoB1* and *rpoD1* alleles on RNA polymerase, we characterized the transcriptional profiles of the CRO^RS^ isolates GCGS1095 (*rpoB1*) and GCGS1014 (*rpoD1*) and the susceptible isolate GCGS0457 by RNA-seq. The transcriptional profiles of the CRO^RS^ isolates were similar to one another but distinct from GCGS0457 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), with 1337 and 1410 annotated ORFs significantly altered in abundance, respectively. The transcriptomic differences we observe may partly reflect the genetic distance between these isolates ([@bib53]), as the resistant strains GCGS1095 and GCGS1014 are more closely related to one another than they are to GCGS0457. We therefore compared GCGS0457 to its isogenic CRO^RS^ transformants GCGS0457 RpoB^R201H^ and GCGS0457 RpoD^E98K^. The *rpoB1* and *rpoD1* alleles each profoundly altered the transcriptional profile of GCGS0457: 1278 annotated ORFs in GCGS0457 RpoD^E98K^ and 1218 annotated ORFs in the GCGS0457 RpoB^R201H^ were differentially expressed relative to the parental GCGS0457 strain. The transcriptional profiles of the two transformants were very similar to one another ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), indicating that these different mutations have similar functional consequences. Overall, a total of 890 annotated ORFs were differentially expressed in all four CRO^RS^ strains (the two CRO^RS^ isolates and two transformants in the GCGS0457 background) compared to GCGS0457. The vast majority of the transcriptional changes are small in magnitude: 805/890 (90%) are less than 2-fold differentially expressed in one or more of the CRO^RS^ strains.

Altered expression of resistance-associated genes such as efflux pumps and β-lactamases is a common mechanism of transcriptionally-mediated drug resistance. Although these strains lack a TEM-1 β-lactamase ([@bib19]), increased expression of the gonococcal MtrCDE efflux pump is known to increase resistance to β-lactams, including cephalosporins ([@bib33]). However, transcription of the operon encoding this pump is not elevated in the CRO^RS^ RNAP mutants ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), nor is it differentially upregulated in response to drug exposure in these strains ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

In vitro evolution studies that evolved cephalosporin resistance in *N. gonorrhoeae* identified inactivating mutations in the type IV pilus pore subunit PilQ ([@bib22]; [@bib60]), although similar *pilQ* mutations have not been identified in clinical isolates, presumably because colonization requires pilus-mediated adhesion to epithelial cells ([@bib23]; [@bib44]). Notably, *pilQ* transcription is reduced in the GCGS0457 *rpoB1* and GCGS0457 *rpoD1* transformants, as well as in the CRO^RS^ isolates GCGS1095 and GCGS1014 ([Figure 4---figure supplements 2](#fig4s2){ref-type="fig"} and [3](#fig4s3){ref-type="fig"}). The effect of hypomorphic *pilQ* expression on cephalosporin susceptibility has not been described, but it is possible that reducing *pilQ* transcript levels may confer the benefits of inactivating *pilQ* mutations without altogether eliminating pilus-mediated attachment and colonization.

CRO^RS^-associated RNAP mutations alter the abundance of cell wall biosynthesis enzymes {#s2-7}
---------------------------------------------------------------------------------------

Since ESCs, like other β-lactams, block cell wall biosynthesis by covalently inhibiting penicillin-binding proteins (PBPs), we examined how CRO^RS^-associated RNAP mutations affect expression of enzymes in this target pathway. *N. gonorrhoeae* encodes four known PBPs ([@bib38]; [@bib45]): the essential high-molecular weight bifunctional transpeptidase/transglycosylase PBP1 (encoded by *ponA*); the essential high-molecular weight transpeptidase PBP2 (encoded by *penA*) ([@bib61]), which is the primary target of ESCs; and the nonessential carboxypeptidases PBP3 (encoded by *dacB*) and PBP4 (encoded by *pbpG*). In addition to these canonical PBPs, *N. gonorrhoeae* genomes include DacC (encoded by *dacC*), a third putative low-molecular weight carboxypeptidase that lacks conserved active site motifs ([@bib38]). A homologue of the L,D-transpeptidase YnhG is also present in the genome, although it has not been reported to be functional in *N. gonorrhoeae*.

Increased expression of drug targets can lead to decreased drug susceptibility, but CRO^RS^-associated RNAP mutations did not increase mRNA or protein abundance of the CRO target PBP2 ([Figure 4](#fig4){ref-type="fig"}). Transcription of the putative L,D-transpeptidase gene *ynhG* is also unchanged in the CRO^RS^ strains ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). By contrast, PBP1 (*ponA*) is upregulated in each of the CRO^RS^ strains compared to GCGS0457, while expression of PBP3, *pbpG*, and *dacC* is decreased in these strains ([Figure 4A--B](#fig4){ref-type="fig"}). Similar expression patterns were observed in the presence of sub-inhibitory CRO ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

![Effect of CRO^RS^-associated RNA polymerase mutations on PBP abundance.\
(**A**) Normalized abundance of transcripts encoding penicillin binding proteins (PBPs) in parental isolates (GCGS0457, GCGS1095, GCGS1014) and RNAP mutant transformants in the GCGS0457 background, measured by RNAseq. (**B**) Relative protein abundance of PBP1, PBP2, and PBP3, as measured by bocillin-FL labeling. Total bocillin-FL signal for each strain was set at 100%. The relative contribution of each PBP to that signal is shown here. PBP4 protein was not observed on these gels, in agreement with previous reports ([@bib49]).](elife-51407-fig4){#fig4}

These altered PBP expression patterns are reflected in the cell wall structure of the CRO^RS^ strains: reduced expression of the carboxypeptidases results in more peptidoglycan with pentapeptide stems ([Figure 5](#fig5){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}), in agreement with reported structural changes of cell walls from strains lacking the DacB carboxypeptidase ([@bib38]). The increased expression of PBP1 in these RNAP mutants does not appear to increase the abundance of crosslinked peptidoglycan ([Figure 5](#fig5){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}).

![Effect of CRO^RS^-associated RNA polymerase mutations on cell wall structure.\
Relative abundance of muropeptide peaks in cell wall digests of GCGS0457 and its CRO^RS^ derivatives, GCGS0457 RpoD^E98K^ and GCGS0457 RpoB^R201H^. Transformant cell walls contain a higher proportion of peptidoglycan with pentapeptide stems (peaks 4, 8, 15b, and 16). Relative abundance values for each muropeptide species (right) were calculated by extracting the peak mass from the total ion chromatogram, integrating the resulting peak area, and dividing by the sum of all of the peak areas within each sample. Shown: mean and standard deviation from 3 biological replicates (data from individual replicates can be found in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Muropeptide species that are significantly altered in abundance each transformant compared to the parental strain GCGS0457 are indicated in bold (p\<0.05 by two-tailed t test). See [Supplementary file 3](#supp3){ref-type="supplementary-material"} for a list of all muropeptide masses detected.\
Figure 5---source data 1.Relative abundance of muropeptide species in individual biological replicates.](elife-51407-fig5){#fig5}

Discussion {#s3}
==========

We have identified five different CRO^RS^-associated RNA polymerase alleles. Three of these -- *rpoB1*, *rpoD1*, and *rpoD2* -- are the genetic basis of high-level reduced ESC susceptibility in clinical isolates with previously unexplained resistance phenotypes. The remaining two arose spontaneously during culture, indicating that the RNAP alleles described in this work are likely only a subset of functionally similar mutations that could arise in clinical isolates. Clinical isolates from diverse genetic backgrounds can achieve high-level CRO^RS^ via these RNAP mutations. This is highlighted by the appearance of the *rpoD2* allele in a second clinical isolate belonging to a genetically distinct clade. Because this isolate is a member of a large clade that includes many closely related isolates, this result illustrates the concerning potential of these mutations to cause *penA*-independent CRO^RS^ in globally distributed strains and the importance of including these mutations in ongoing surveillance efforts.

Among the isolates of the GISP collection, there was no evidence for sustained transmission of the CRO^RS^ RNAP mutant isolates ([Figure 1](#fig1){ref-type="fig"}), perhaps indicating that fitness costs associated with these RNAP variants have prevented their spread. However, it is important to note that the CRO^RS^ isolates GCGS1095, GCGS1014, and GCGS1013 are susceptible to azithromycin ([Table 2](#table2){ref-type="table"}). This susceptibility may be an alternative explanation for the failure of these RNAP mutations to spread in an era of azithromycin/ceftriaxone combination therapy.

RNA polymerase mutations have been identified as mediators of diverse phenotypes, such as reduced susceptibility to phage lysis ([@bib4]; [@bib39]) and antimicrobial drugs, including cell wall biosynthesis inhibitors ([@bib10]; [@bib27]; [@bib29]; [@bib42]; [@bib55]). These mutations often arise during in vitro evolution experiments, and are typically described as artifacts of in vitro conditions, as the presumed pleiotropy of such mutations is typically thought to be prohibitively deleterious. This description of resistance-associated RNAP mutations in isolates collected from symptomatic patients demonstrates that, at least in the case of CRO^RS^ in *N. gonorrhoeae*, clinical isolates can acquire resistance via RNAP mutation while still maintaining sufficient fitness to cause disease. Similar results have been reported regarding the role of *rpoB* mutation in decreased susceptibility to vancomycin in staphylococcal species ([@bib20]; [@bib30]; [@bib56]).

In accordance with this model, the RNAP mutations identified in these CRO^RS^ isolates result in an apparently narrowly-targeted phenotypic change: RNAP mutants acquire resistance to cephalosporins but not other classes of antimicrobial drugs, show no growth defect in vitro, and display broad but small-magnitude changes to transcript levels, indicating that RNAP mutation may be a valid approach to fine-tuning bacterial physiology for enhanced survival under certain adverse conditions, such as antibiotic exposure.

The observation that the RNAP mutations identified here neither decrease susceptibility to other antimicrobials nor alter growth phenotypes supports the hypothesis that these mutations generate a 'fine-tuning' cephalosporin-specific resistance mechanism, as opposed to a large-scale physiological shift toward a generally antibiotic-tolerant state. Altered activity of the RNA polymerase transcription machinery likely results in this type of drug-specific reduced susceptibility. RNAP variants differentially express multiple transcripts relating to the cephalosporin mode of action. For example, while PBP2 levels are unaffected, the increase of PBP1 expression may contribute to cephalosporin resistance. PBP1 and PBP2 both catalyze transpeptidation, but PBP1 belongs to a class of enzymes that is not efficiently inhibited by third-generation cephalosporins ([@bib26]), suggesting that increased PBP1 levels may partly compensate for CRO-inhibited PBP2 during drug treatment. The RNAP variants simultaneously reduce D,D-carboxypeptidase expression, increasing the pool of pentapeptide peptidoglycan monomers available for transpeptidation by PBP1 and PBP2. Decreased expression of pilus pore components in these mutants may also contribute to CRO^RS^ by reducing permeability of the outer membrane to cephalosporins ([@bib7]; [@bib22]; [@bib37]; [@bib60]). These expression changes and others may work additively or synergistically to increase drug resistance. The pleiotropy of RNAP mutations may thus enable a multicomponent resistance mechanism to emerge from a single genetic change.

This result has important implications regarding the biology underlying cephalosporin resistance, the potential for de novo evolution of resistance under cephalosporin monotherapy, and the accuracy of sequence-based diagnostics. The identification of five independent mutations in two separate components of the RNA polymerase machinery illustrates challenges faced by computational genomics strategies to define new resistance alleles, especially because there are other variants in these genes -- such as rifampicin resistance mutations in *rpoB* -- that do not confer CRO^RS^. Continued isolate collection, phenotypic characterization, and traditional genetic techniques will be critical for defining emerging resistance mechanisms ([@bib21]). The observation that multiple lineages can gain CRO resistance through RNAP mutations further underscores the need to monitor for the development of CRO^RS^ through pathways other than *penA* mutation, particularly as the ESCs are increasingly relied upon for treatment. Identifying these alternative genetic mechanisms of reduced susceptibility is needed to support the development of accurate and reliable sequence-based diagnostics that predict CRO susceptibility, as well as to aid in the design of novel therapeutics.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                         Designation                                    Source or\                        Identifiers                Additional\
  (species) or\                                                                                        reference                                                    information
  resource                                                                                                                                                          
  ----------------------------------------------------- ---------------------------------------------- --------------------------------- -------------------------- ------------------------------------
  Gene (*Neisseria gonorrhoeae*)                        *penA*                                         *Neisseria gonorrhoeae* PubMLST   NEIS1753                   

  Gene (*Neisseria gonorrhoeae*)                        *ponA*                                         *Neisseria gonorrhoeae* PubMLST   NEIS0414                   

  Gene (*Neisseria gonorrhoeae*)                        *rpoB*                                         *Neisseria gonorrhoeae* PubMLST   NEIS0123                   

  Gene (*Neisseria gonorrhoeae*)                        *rpoD*                                         *Neisseria gonorrhoeae* PubMLST   NEIS1466                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0457                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS1095                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS1014                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS1013                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0364                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0092                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0126                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0161                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0249                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0275                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0336                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0353                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0374                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0465                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0489                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0497                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0501                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0524                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0560                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0576                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0698                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCGS0769                                       ([@bib19])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   GCPH44                                         ([@bib11])                                                   

  Strain, strain background (*Neisseria gonorrhoeae*)   28BL                                           Gift of S. Johnson                                           

  Chemical compound, drug                               Ceftriaxone disodium salt hemi(heptahydrate)   Sigma Aldrich                     Cat. \# C5793              

  Chemical compound, drug                               Ceftriaxone Etest                              bioMérieux                        SKU \# 412302 and 412300   

  Chemical compound, drug                               Penicillin G Etest                             bioMérieux                        SKU \# 412262              

  Chemical compound, drug                               Ertapenem Etest                                bioMérieux                        SKU \# 531640              

  Chemical compound, drug                               Cefixime trihydrate                            Sigma Aldrich                     Cat. \# 18588              

  Chemical compound, drug                               Azithromycin                                   Sigma Aldrich                     Cat. \# PHR1088            

  Chemical compound, drug                               Tetracycline hydrochloride                     Sigma Aldrich                     Cat. \# T7660              

  Chemical compound, drug                               Ciprofloxacin                                  Sigma Aldrich                     Cat. \# 17850              

  Chemical compound, drug                               Rifampicin                                     Chem-Impex                        Cat. \# 00260              

  Chemical compound, drug                               Bocillin FL penicillin, sodium salt            Thermo Fisher                     Cat. \# B13233             

  Sequence-based reagent                                RpoB-US                                        This paper                        PCR primers                ATGCCGTCTGAATATCAGATTGATGCGTACCGTT

  Sequenced-based reagent                               RpoB-DS                                        This paper                        PCR primers                CGTACTCGACGGTTGCCCAAG

  Sequenced-based reagent                               RpoD-US                                        This paper                        PCR primers                AACTGCTCGGACAGGAAGCG

  Sequenced-based reagent                               RpoD-DS                                        This paper                        PCR primers                CGCGTTCGAGTTTGCGGATGTT
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bacterial strains and culture conditions {#s4-1}
----------------------------------------

Strains are presented in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. Metadata for the 1102 GISP isolates included in [Figure 1](#fig1){ref-type="fig"} was previously published ([@bib19]). Except where otherwise specified, *N. gonorrhoeae* was cultured on GCB agar (Difco) with Kellogg's supplements (GCB-K) ([@bib23]) at 37°C in a 5% CO~2~ atmosphere. Antibiotic susceptibility testing of *N. gonorrhoeae* strains was performed on GCB media supplemented with 1% IsoVitaleX (Becton Dickinson) via agar dilution (for cefixime, azithromycin, tetracycline, ciprofloxacin, and rifampicin) or Etest (bioMérieux) (for ceftriaxone, penicillin G, and ertapenem). A CRO^RS^ breakpoint of ≥0.125 μg/mL was used, in accordance with the GISP breakpoint ([@bib25]).

Transformation of reduced cephalosporin susceptibility with genomic DNA {#s4-2}
-----------------------------------------------------------------------

The CRO^S^ recipient strain GCGS0457 was transformed with genomic DNA from GCGS1014 and GCGS1095. Transformations were conducted in liquid culture as described ([@bib35]; [@bib52]). Briefly, piliated *N. gonorrhoeae* was suspended in GCP medium (15 g/L protease peptone 3, 1 g/L soluble starch, 4 g/L dibasic K~2~HPO~4~, 1 g/L monobasic KH~2~PO~4~, 5 g/L NaCl) with Kellogg's supplement, 10 mM MgCl~2~, and approximately 100 ng genomic DNA. Suspensions were incubated for 10 min at 37°C with 5% CO~2~. Transformants were allowed to recover on nonselective agar for 4--5 hr. After recovery, transformants were plated on GCB-K ceftriaxone gradient agar plates, which were prepared by allowing a 40 μL droplet of 5 μg/mL ceftriaxone to dry onto a GCB-K agar plate. Transformations performed with GCGS0457 genomic DNA served as controls to monitor for spontaneous CRO^RS^ mutation. After outgrowth at 37°C in 5% CO~2~, colonies growing within the ceftriaxone zone of inhibition were subcultured for further analysis.

Transformation of RNA polymerase mutations {#s4-3}
------------------------------------------

\~1.5 kb PCR fragments surrounding the *rpoB* and *rpoD* loci of interest were amplified using the primer pairs RpoB-US (5'-[ATGCCGTCTGAA]{.ul}TATCAGATTGATGCGTACCGTT-3') and RpoB-DS (5'-CGTACTCGACGGTTGCCCAAG-3') or RpoD-US (5'-AACTGCTCGGACAGGAAGCG-3') and RpoD-DS (5'-CGCGTTCGAGTTTGCGGATGTT-3'). The 12 bp DNA uptake sequence (DUS) for *N. gonorrhoeae* ([@bib3]) was added to the 5' end of the RpoB-US primer (underlined) to enhance transformation efficiency with the PCR product; a DUS was not added to the RpoD-US or RpoD-DS primers, as the PCR product amplified by these primers includes two endogenous DUS regions. CRO^S^ recipient strains were transformed with 200--300 ng purified PCR products and transformants were selected for CRO^RS^ as above. Transformation reactions performed with wildtype alleles (*rpoB^+^* from GCGS1014; *rpoD^+^* from GCGS1095) served as controls to monitor for spontaneous CRO^RS^ mutation.

The following isolates were used for experiments examining the compatibility of *rpoB1*-mediated CRO^RS^ with diverse genetic backgrounds: GCGS0092, GCGS0275, GCGS0336, GCGS0465, GCGS0524 (all successfully); and GCGS0126, GCGS0161, GCGS0249, GCGS0353, GCGS0374, GCGS0489, GCGS0497, GCGS0501, GCGS0560, GCGS0576, GCGS0698, and GCGS0769. CRO susceptibility and RNA polymerase allele information for each of these isolates is available in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Sequencing and analysis {#s4-4}
-----------------------

Following undirected transformation of GCGS0457 with GCGS1014 or GCGS1095 genomic DNA, or directed transformation of GCGS0457 with PCR products, CRO^RS^ transformants were analyzed by whole genome sequencing. Genomic DNA of transformants was purified with the PureLink Genomic DNA Mini kit (Life Technologies) and sequencing libraries were prepared as described [@bib24]. Paired-end sequencing of these libraries was performed on an Illumina MiniSeq (Illumina). Reads were aligned to the de novo assembly of the GCGS0457 genome (European Nucleotide Archive, accession number ERR855051) using bwa v0.7.8 ([@bib32]), and variant calling was performed with pilon v1.22 ([@bib54]).

Whole genome assembly and annotation {#s4-5}
------------------------------------

Whole genome sequencing reads from the GISP collection were assembled using Velvet ([@bib59]) as previously described [@bib19]. Spades v 3.12 ([@bib5]) was used for de novo assembly of GCPH44. Contigs were corrected by mapping reads back to the assembly (\--careful), and contigs with less than 10X coverage or fewer than 500 nucleotides were removed. Reads were also mapped to the reference genome NCCP11945 (NC_011035.1) with bwa mem v0.7.15 ([@bib32]). Variants were identified with Pilon v 1.16 ([@bib54]) using a minimum depth of 10 and minimum mapping quality of 20. SNPs, small deletions, and uncertain positions were incorporated into the reference genome to create pseudogenomes. For each isolate in the GISP collection and in the United Kingdom collection ([@bib11]), the sequence of RNA polymerase components was identified using BLASTn (ncbi-blast v2.2.30) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

Phylogenetic analysis {#s4-6}
---------------------

Recombinant regions of the pseudogenome alignment were detected by Gubbins ([@bib9]), and the maximum likelihood phylogenetic tree was estimated from this masked alignment using RAxML ([@bib48]). The phylogeny was visualized using ITOL ([@bib31]).

Growth curves {#s4-7}
-------------

Bacterial cells grown overnight on GCB-K plates were suspended in tryptic soy broth to OD~600~ 0.01. Three replicate GCB-K plates per time point were inoculated with 0.1 mL of this suspension and incubated at 37°C with 5% CO~2~. At each time point, the lawn of bacterial growth from each of three replicate plates was suspended in tryptic soy broth. Serial dilutions were plated on GCB-K to determine total CFUs per plate. CFU counts were normalized to the initial inoculum density (CFUs measured at time 0) for each replicate.

Transmission electron microscopy {#s4-8}
--------------------------------

Bacterial cells grown overnight on GCB-K plates were suspended in liquid GCP medium with 1% Kellogg's supplement and 0.042% NaHCO~3~ to OD~600~ 0.1. Suspensions were incubated at 37°C with aeration for 2 hr to allow cultures to return to log phase. Cell pellets were collected by centrifugation and fixed for at least two hours at room temperature in 0.2M cacodylate buffer with 2.5% paraformaldehyde, 5% glutaraldehyde, and 0.06% picric acid. Fixed pellets were washed in 0.1M cacodylate buffer and postfixed with 1% Osmiumtetroxide (OsO~4~)/1.5% Potassiumferrocyanide (KFeCN6) for 1 hr, washed 2x in water, 1x Maleate buffer (MB) 1x and incubated in 1% uranyl acetate in MB for 1 hr followed by two washes in water and subsequent dehydration in grades of alcohol (10 min each; 50%, 70%, 90%, 2 × 10 min 100%). The samples were then put in propyleneoxide for 1 hr and infiltrated ON in a 1:1 mixture of propyleneoxide and TAAB Epon (Marivac Canada Inc St. Laurent, Canada). The following day the samples were embedded in TAAB Epon and polymerized at 60 degrees C for 48 hr. Ultrathin sections (\~60 nm) were cut on a Reichert Ultracut-S microtome, picked up on to copper grids stained with lead citrate and examined in a JEOL 1200EX Transmission electron microscope or a TecnaiG² Spirit BioTWIN and images were recorded with an AMT 2 k CCD camera.

Transcriptomics {#s4-9}
---------------

RNA isolation and sequencing was performed from *N. gonorrhoeae* strains as described [@bib52]. Bacterial cells grown on GCB-K plates for 17 hr were suspended in liquid GCP medium with 1% IsoVitaleX and 0.042% NaHCO~3~ to OD~600~ 0.1. Suspensions were incubated at 37°C with aeration for 2--3 hr to allow cultures to return to log phase. Cells were collected to measure baseline transcriptional profiles. For samples measuring the effect of drug exposure, 0.008 μg/mL CRO was added and cultures were incubated at 37°C for an additional 90 min before cell collection. RNA was purified with the Direct-Zol kit (Zymo). Transcriptome libraries were prepared at the Broad Institute at the Microbial 'Omics Core using a modified version of the RNAtag-seq protocol ([@bib47]). Five hundred nanograms of total RNA was fragmented, depleted of genomic DNA, dephosphorylated, and ligated to DNA adapters carrying 5'-AN8-3' barcodes of known sequence with a 5' phosphate and a 3' blocking group. Barcoded RNAs were pooled and depleted of rRNA using the RiboZero rRNA depletion kit (Epicentre). Pools of barcoded RNAs were converted to Illumina cDNA libraries in two steps: (i) reverse transcription of the RNA using a primer designed to the constant region of the barcoded adapter with addition of an adapter to the 3' end of the cDNA by template switching using SMARTScribe (Clontech) as described previously ([@bib63]); (ii) PCR amplification using primers whose 5' ends target the constant regions of the 3' or 5' adapter and whose 3' ends contain the full Illumina P5 or P7 sequences. cDNA libraries were sequenced on the Illumina Nextseq 500 platform to generate 50 bp paired-end reads. Barcode sequences were removed, and reads were aligned to the FA1090 reference genome. Differential expression analysis was conducted in DESeq2 v.1.16.1 ([@bib34]).

Sequence data availability {#s4-10}
--------------------------

Genomic and transcriptomic read libraries are available from the NCBI SRA database (accession number PRJNA540288).

PBP abundance measurement {#s4-11}
-------------------------

Protein abundance of PBP1, PBP2, and PBP3 was calculated using the fluorescent penicillin derivative bocillin-FL (Thermo Fisher). *N. gonorrhoeae* strains from overnight cultures were suspended in liquid GCP medium supplemented with 1% IsoVitalex and 0.042% NaHCO~3~ to a density of OD~600~ 0.1. Suspensions were incubated with aeration at 37°C for 2.5--3 hr. Bacterial cells were collected by centrifugation, washed once with 1 mL of sterile phosphate-buffered saline (PBS), and resuspended in PBS 5 μg/mL bocillin-FL and 0.1% dimethyl sulfoxide (DMSO) to a final concentration of 1 mL of OD~600~ 0.5 per 50 μL suspension. Bocillin-FL suspensions were incubated for 5 min. An equal volume 2x SDS-PAGE sample buffer (Novex) was added and samples were boiled for 5 min. Proteins in 30 μL of each suspension were separated by SDS-PAGE on 4--12% Tris-Glycine protein gels (Novex), which were visualized on a Typhoon imager (Amersham) (excitation 488 nm/emission 526 nm) to detect bocillin-FL fluorescence. Densitometry was performed with ImageJ ([@bib46]). Total bocillin-FL fluorescent signal was calculated for each sample, and the proportional contribution of individual PBPs to this signal was reported.

Muropeptide analysis {#s4-12}
--------------------

*N. gonorrhoeae* strains were cultured for approximately 18 hr at 37°C with agitation in GCP medium supplemented with Kellogg's reagent and 0.042% NaHCO~3~. Peptidoglycan was isolated and digested as described [@bib28] with minor modifications. Briefly, bacterial cells were pelleted by centrifugation, suspended in 1 mL 1M NaCl, and incubated at 100°C for 20 min. Samples were centrifuged for one minute at 18,000 × *g*. Pellets were washed three times with water, suspended in 1 mL water, and placed in a bath sonicator for 30 min. 0.5 mL 0.1M Tris pH 6.8, 40 μg/mL RNase, and 16 μg/mL DNase were added to each sample; samples were incubated with shaking at 37°C for two hours, with the addition of 16 μg/mL trypsin after the first hour of incubation. Samples were heated to 100°C for 5 min to inactivate enzymes, then centrifuged for 3 min at 18,000 × *g* to pellet peptidoglycan. Pellets were washed with 1 mL aliquots of water until the suspension pH measured between 5 and 5.5. Peptidoglycan was then resuspended in 0.2 mL 12.5 mM NaH~2~PO~4~ pH 5.5 with 500 U/mL mutanolysin and incubated with shaking at 37°C for 16 hr. Samples were heated to 100°C for 5 min to inactivate mutanolysin and centrifuged for 5 min at 18,000 × *g* to pellet debris. The supernatant, containing solubilized muropeptides, was removed to new tubes, and 50 μL 10 mg/mL NaBH~4~ was added to each. Samples were incubated at room temperature for 30 min and then the pH was adjusted to 2--3 with 85% H~3~PO~4~.

LC-MS was conducted using an Agilent Technologies 1200 series HPLC in line with an Agilent 6520 Q-TOF mass spectrometer operating with electrospray ionization (ESI) and in positive ion mode. The muropeptide fragments were separated on a Waters Symmetry Shield RP18 column (5 μm, 4.6 × 250 mm) using the following method: 0.5 mL/minute solvent A (water, 0.1% formic acid) for 10 min followed by a linear gradient of 0% solvent B (acetonitrile, 0.1% formic acid) to 20% B over 90 min.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"RNA polymerase mutations cause cephalosporin resistance in clinical Neisseria gonorrhoeae isolates\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gisela Storz as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: William Shafer (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript reports mutations in RNA polymerase (RNAP) that confer elevated resistance to ceftriaxone in *N. gonorrhoeae*. The authors propose a mechanism whereby the mutations in RNAP lead to over-expression of PBP1, which contributes to the ceftriaxone/cefixime resistance. These findings are significant as they reveal a new mechanism for ceftriaxone resistance that could impact the problem of cephalosporin resistance.

Essential revisions:

1\) Have the authors introduced the *rpoB* or *rpoD* mutations into isogeneic strains that differ only in the presence of a wild-type or mutant *ponA* gene? It strikes me that all of the clinical isolates have the *ponA* mutation. The question is really whether the host strain has to have a mutant *ponA* or is just over-expression of *ponA* sufficient for *rpoB/D*-driven resistance. The same is true for the *mtrR* mutation since loss of MtrR activity may impact transcription of *ponA* and the *rpoB*/D mutations could compensate.

2\) The authors indicate that the *rpoB/rpoD* mutations do not result in a growth defect. The methodology used and the description is difficult to follow as written. Did they perform a competitive growth experiment in which parent and transformant strains were co-cultivated in broth and then sampled over time to distinguish the two strains? In any event, it would be good to present a standard growth curve with OD and CFU/mL values.

3\) If known, please state the spontaneous mutation rates for *rpoB/rpoD* mutations with respect to ceftrixone resistance. I ask this because in one case spontaneous mutants in transformation experiments were not obtained (although the number of bacteria may have been too low to detect). In the second case, spontaneous resistant mutants were obtained.

4\) The claim of altered peptidoglycan structure in the presence of the RNAP mutations appears weak in the absence of statistical analysis of peaks (Figure 5), therefore there is concern about the rigor of these particular experiments. Only the abundance of pentapeptides changes and the difference is two-fold. The data shown are said to be representative of three independent experiments, and it should therefore be facile to derive errors for the abundance of PG species.

5\) There are some discrepancies between Table 1 and the described written results. Subsection "A single missense mutation in *rpoB* is the genetic basis for reduced ceftriaxone susceptibility in the clinical isolate GCGS1095", last paragraph. The MIC of the transformant GCGS0457 RpoB^R201H^ was not similar to the MIC of the parental strain GCGS1095 -- it was 2x less. How many times were the MICs repeated and how much variation was observed? Were all MICs conducted using the same method or were some strains tested by agar dilution and others by Etest? I agree that the transformation resulted in a highly elevated CRO MIC but the descriptions should be exact.

6\) The written text states that "GCGS0457 RpoD^E98K^ had a CRO MIC of 0.125" while Table 1 indicates an MIC of 0.25. This is not similar to the parental strain.

7\) Figure 1. A better description of the database used to generate this tree would be helpful. Perhaps this could be included in the Materials and methods section. The tree should be enlarged for clarity, including the insert. The dots on the phylogenetic tree of the insert should be connected with relevant strain numbers for easier interpretation. How many GISP isolates does this tree include? The third paragraph of the subsection "RNA polymerase mutations explain CRO^RS^ in other clinical isolates" mentions 1102 genomes; this could be included in the figure and in a better description of the GISP data base in the Materials and methods.

8\) Supplementary file 1 should be reformatted to identify variants, possibly by bolding, coloring, or separating the variants to distinguish them.

9\) Section on clinical isolates from multiple lineages. There is no information on what isolates were transformed -- the panel of 17 should be named (Materials and methods section) and the exact transformation procedure described -- was the PCR product used for transformation? Is a onetime (subsection "Clinical isolates from multiple lineages can achieve high-level CRO^RS^ via a single nucleotide change in *rpoB*", last paragraph) transformation procedure really indicative of a failed transformation? These descriptions are quite incomplete, and could be described briefly but succinctly. Presumably, some of these strains are indicated in Figure 1, although the figure is difficult to read.

10\) Could it be that the mutants may have prolonged stationary phase survival (Figure 3)?

11\) The authors indicate that the transcription of *mtrCDE* was not elevated. It appears that transcription was uniformly decreased in mutant strains. Is this decrease significant? What would/do these results imply?
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Author response

> Essential revisions:
>
> 1\) Have the authors introduced the rpoB or rpoD mutations into isogeneic strains that differ only in the presence of a wild-type or mutant ponA gene? It strikes me that all of the clinical isolates have the ponA mutation. The question is really whether the host strain has to have a mutant ponA or is just over-expression of ponA sufficient for rpoB/D-driven resistance. The same is true for the mtrR mutation since loss of MtrR activity may impact transcription of ponA and the rpoB/D mutations could compensate.

We have now updated the manuscript to address these points. First, with regard to PonA: our transformation experiments showed that the PBP1 L421P variant is not required for RNAP-mediated CRO^RS^. Among the panel of isolates that have been successfully transformed to a CRO^RS^ phenotype via *rpoB1*, three isolates -- GCGS0275, GCGS0465, and GCGS0524 -- lack this *ponA* variant. This information is available in the new Supplementary file 2 and discussed in the expanded transformation section that has been included in response to point 9 (below). Although we have not constructed an isogenic strain pair to directly determine the effects of the PBP1 L421P mutation, we believe the data above support that this variant is not required.

Second, with regard to MtrR: similar to PonA, the variant allele of *mtrR* that is present in the parental CRO^RS^ isolates GCGS1013, GCGS1014, GCGS1095, and GCGS0364 is not required for RNAP-mediated reduced CRO susceptibility. Several *mtrR* alleles are represented among the panel of isolates that were successfully transformed with *rpoB1*, including the wildtype allele in isolate GCGS0275. This information is included in Supplementary file 2.

> 2\) The authors indicate that the rpoB/rpoD mutations do not result in a growth defect. The methodology used and the description is difficult to follow as written. Did they perform a competitive growth experiment in which parent and transformant strains were co-cultivated in broth and then sampled over time to distinguish the two strains? In any event, it would be good to present a standard growth curve with OD and CFU/mL values.

In preliminary growth curve experiments, we found that tracking growth of cultures growing in liquid GCP media supplemented with 1% IsoVitaleX and 0.042% NaHCO~3~ by OD~600~ measurements did not show the same time-dependent trends as tracking growth of these cultures by dilution and CFU plating. Similar results have been reported before, as in Figure 1 of Vincent et al. (2018, mBio, e01905-17).

For completeness, we have performed the suggested experiment. Briefly, the liquid cultures of GCGS0457 and its CRO^RS^ transformants GCGS0457 *rpoD1* and GCGS0457 *rpoB1* were seeded in GCP supplemented with 1% IsoVitaleX and 0.042% NaHCO~3~ at a starting density of approximately OD~600~ = 0.1. Culture density was monitored by spectrometry and dilution plating every 2 hours. Here we show mean and standard deviation of 3 technical replicates; the data are representative of 2 independent experiments.
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The purpose of this growth curve in our work is not to argue that the RNAP mutations have no effect on fitness; indeed, given the broad perturbations we observe in transcriptional data, we find it likely that these RNAP mutants might be profoundly growth disadvantaged in many physiologically relevant conditions. Instead, we wished to determine whether the elevated MIC phenotype we observe in the antimicrobial sensitivity testing we report here might be related to a slow-growth phenotype. Therefore, we measured the growth of our strains of interest as they were growing on GCB agar plates, as this is the growth condition in which MIC measurements were performed, and therefore the condition most closely suited to determining how growth rate differences might affect results of the MIC assay.

> 3\) If known, please state the spontaneous mutation rates for rpoB/rpoD mutations with respect to ceftrixone resistance. I ask this because in one case spontaneous mutants in transformation experiments were not obtained (although the number of bacteria may have been too low to detect). In the second case, spontaneous resistant mutants were obtained.

We have not measured the rate of spontaneous RNAP CRO^RS^ mutation. All selection for de novo or transformed CRO^RS^ RNAP mutants in this work was performed by plating bacterial suspensions on a plate containing a concentrated spot of CRO and identifying colonies growing within the zone of inhibition. This method improves the recovery CRO^RS^ mutants, which often appear close to the margin of the zone of inhibition; we have found that plating efficiency of CRO^RS^ strains on even modest CRO concentrations is poor, perhaps explaining this pattern. However, as this method does not permit the robust quantification of the number of CRO^RS^ CFUs over the entire surface of a plate, it is not compatible with traditional methods for measuring mutation or transformation rates.

> 4\) The claim of altered peptidoglycan structure in the presence of the RNAP mutations appears weak in the absence of statistical analysis of peaks (Figure 5), therefore there is concern about the rigor of these particular experiments. Only the abundance of pentapeptides changes and the difference is two-fold. The data shown are said to be representative of three independent experiments, and it should therefore be facile to derive errors for the abundance of PG species.

We appreciate this opportunity to make the case more compellingly, and we have now included statistical information in Figure 5, as well as data from individual experiments in Figure 5---source data 1.

> 5\) There are some discrepancies between Table 1 and the described written results. Subsection "A single missense mutation in rpoB is the genetic basis for reduced ceftriaxone susceptibility in the clinical isolate GCGS1095", last paragraph. The MIC of the transformant GCGS0457 RpoB^R201H^ was not similar to the MIC of the parental strain GCGS1095 -- it was 2x less. How many times were the MICs repeated and how much variation was observed? Were all MICs conducted using the same method or were some strains tested by agar dilution and others by Etest? I agree that the transformation resulted in a highly elevated CRO MIC but the descriptions should be exact.

In general, two-fold variation in MIC determination is considered within the boundaries of technical variation -- particularly when MIC testing is done by agar dilution, which determines MIC only to the nearest doubling dilution. The language in this section was chosen with this in mind.

In the original manuscript, reported MICs were a mixture of MICs determined by agar dilution, by Etest, and by agar dilution from the Centers for Disease Control and Prevention's original GISP report (see Grad et al., 2016). We thank the reviewers for their suggestion that we improve the clarity of this section. For consistency, we are now showing MIC data that was collected either by Etest only or by agar dilution only, depending on the drug being tested (see Materials and methods, subsection "bacterial strains and culture conditions"). This required additional MIC testing to replace some MIC values that had previously been determined by agar dilution with new MIC values determined by Etest. MIC values in Tables 1 and 2 and Supplementary file 2 have been altered to reflect this more recent Etest data, which does not qualitatively change any of the interpretations of our paper, but which allows MIC determination at a finer resolution than agar dilution.

> 6\) The written text states that "GCGS0457 RpoD^E98K^ had a CRO MIC of 0.125" while Table 1 indicates an MIC of 0.25. This is not similar to the parental strain.

This discrepancy was an error, originating from reporting the results of different replicate experiments in these two places (see point 5 above). We now report the redone Etest results, both in the text and in Tables 1 and 2.

> 7\) Figure 1. A better description of the data base used to generate this tree would be helpful. Perhaps this could be included in the Materials and methods section. The tree should be enlarged for clarity, including the insert. The dots on the phylogenetic tree of the insert should be connected with relevant strain numbers for easier interpretation. How many GISP isolates does this tree include? The third paragraph of the subsection "RNA polymerase mutations explain CRO^RS^ 105 in other clinical isolates" mentions 1102 genomes; this could be included in the figure and in a better description of the GISP data base in the Materials and methods.

Figure 1 has been enlarged, and we have added additional annotations.

This phylogeny includes the 1102 genomes from the GISP project (Grad et al., 2016), plus the GCPH44 isolate identified from the De Silva et al., 2016 report. The figure legend has been updated to include this information. Metadata for the isolates in the GISP strain collection is available in the Grad et al., 2016 reference; the Materials and methods section has been revised to make this clear.

> 8\) Supplementary file 1 should be reformatted to identify variants, possibly by bolding, coloring, or separating the variants to distinguish them.

Variants in this file, Supplementary file 1, have been bolded for emphasis. We also note that, if opened in Excel, this file is sortable by gene variant.

> 9\) Section on clinical isolates from multiple lineages. There is no information on what isolates were transformed -- the panel of 17 should be named (Materials and methods section) and the exact transformation procedure described -- was the PCR product used for transformation? Is a onetime (subsection "Clinical isolates from multiple lineages can achieve high-level CRO^RS^ via a single nucleotide change in rpoB", last paragraph) transformation procedure really indicative of a failed transformation? These descriptions are quite incomplete, and could be described briefly but succinctly. Presumably, some of these strains are indicated in Figure 1, although the figure is difficult to read.

We have expanded the description of this experiment in the text, listed the 17 isolates used for this panel in the Materials and methods section, included the 5 successful isolates in Figure 1, and added a table (Supplementary file 2) giving more detail about these isolates.

We agree that a single failed transformation experiment into any given clinical isolate does not represent strong evidence for genetic incompatibility and we have updated the text to reflect this.

> 10\) Could it be that the mutants may have prolonged stationary phase survival (Figure 3)?

The growth curve data in Figure 3 suggests that these strains may have altered growth or survival phenotypes in stationary phase, and we look forward to exploring this possibility in follow-up work to more thoroughly characterize the effects of CRO^RS^-associated RNAP mutation on bacterial physiology. As the purpose of the growth curve experiment in the context of this study was to rule out slow growth as an explanation for increased growth of RNAP mutants on ceftriaxone MIC plates, we have not focused on the stationary phase portion of our growth curve, as differences in survival at this point would likely not affect MIC interpretation.

> 11\) The authors indicate that the transcription of mtrCDE was not elevated. It appears that transcription was uniformly decreased in mutant strains. Is this decrease significant? What would/do these results imply?

This decrease is significant for *mtrC* and *mtrE*, as well as for *mtrD* in all cases except for the comparison of the GCGS0457 *rpoB1* transformant with GCGS0457, in which this decrease failed to meet the significance threshold (Benjamini-Hochberg adjusted p value 0.06 for this comparison). Interestingly, the decrease in transcription through the *mtrCDE* operon we observe occurs in the presence of a similar magnitude decrease in transcription of the *mtrR* repressor; the change we see in the *mtr* regulon is not coherent. Perhaps this is evidence for a general derangement or perturbation of transcriptional regulation broadly in RNAP mutants. In the context of RNAP-mediated CRO^RS^, the apparently decreased transcription of *mtrCDE* in the RNAP mutants is evidence that the concomitant CRO^RS^ phenotype is not due to increased drug efflux via the Mtr pump.
